AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19502478
Drug: Behavioral Couples
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral Couples Therapy (BCT)
Trial: 10742638
Drug: Individual-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual-based treatment (IBT)
Trial: 28050642
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one tablet)
Trial: 28466022
Drug: In-plane injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-plane injection
Trial: 28466022
Drug: Out-of-plane injection
RxNorm normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Out-of-plane injection
Trial: 27004917
Drug: Fibrinogen 3g
RxNorm normalized name: fibrinogen
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen 3g infusion
Trial: 19712040
Drug: Whole-virus H5N1
RxNorm normalized name: INFLUENZA A VIRUS H5N1 WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-virus H5N1 clade 1 A/Vietnam vaccine (2-dose priming regimen)
Trial: 19712040
Drug: 7.5-microg dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5-microg dose of a clade 2.1 A/Indonesia vaccine (booster)
Trial: 17513402
Drug: Gamma-linolenate (GLA)
RxNorm normalized name: gamma-linolenate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gamma-linolenate (GLA) 890 mg/d (5 g/d borage oil)
Trial: 17513402
Drug: Olive oil
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olive oil (5 g/d)
Trial: 14701773
Drug: PS‐341 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PS‐341 1.5 mg/m(2) administered intravenously twice weekly for 2 weeks every 21 days, with dose escalation to 1.7 mg/m(2) in absence of grade 3 to 4 toxicities.
Trial: 9441058
Drug: 6-month short-course
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month short-course chemotherapy regimen (SCC) with rifampicin, isoniazid and pyrazinamide for 2 months followed by rifampicin with isoniazid for another 4 months (6R series)
Trial: 7951290
Drug: Contract-relax treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contract-relax treatment
Trial: 7951290
Drug: Leg pull
RxNorm normalized name: Crab leg
DrugBank: Crab leg (DB11011)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leg pull treatment
Trial: 3108930
Drug: L-deprenyl 10
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-deprenyl 10 mg/day
Trial: 3108930
Drug: L-deprenyl 40
RxNorm normalized name: L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-deprenyl 40 mg/day
Trial: 29966958
Drug: Supplemental heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplemental heat wrap therapy
Trial: 29966958
Drug: Multimodal treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multimodal treatment without supplemental heat wrap therapy
Trial: 27052212
Drug: Clinical medication
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical medication review followed by a pharmaceutical care plan
Trial: 19387398
Drug: Thermogenic nutritional
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermogenic nutritional supplement
Trial: 22088165
Drug: In-home interdisciplinary
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In-home interdisciplinary care management intervention combining palliative care and geriatric medicine approaches.
Trial: 17629089
Drug: lafutidine 10
RxNorm normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lafutidine 10 mg
Trial: 26201312
Drug: LPZ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPZ 30 mg
Trial: 11383262
Drug: Occlusal adjustment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal adjustment therapy
Trial: 11383262
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of splint and occlusal adjustment therapy
Trial: 7816382
Drug: Dipyridamole infusion
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole infusion
Trial: 3862151
Drug: Amphetamine 30
RxNorm normalized name: dextroamphetamine 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine 30 mg, p.o.
Trial: 26036190
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) with aspirin
Trial: 26323997
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 60 μg/week
Trial: 26323997
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 120 μg/week
Trial: 26323997
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa 240 μg/week
Trial: 23922479
Drug: Continuous sedation
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sedation (group Cc)
Trial: 18771838
Drug: One-visit root
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One-visit root canal treatment
Trial: 23792399
Drug: Two-visit root
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-visit root canal treatment
Trial: 16303215
Drug: Single nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single nasal dose of vaccine containing 15, 30, or 45 microg of each of the three HA antigens
Trial: 16303215
Drug: Two nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two nasal doses containing 30 microg of each HA, separated by 2 weeks
Trial: 16303215
Drug: Vaccine (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine (all doses)
Trial: 10957689
Drug: Comprehensive hypertension
RxNorm normalized name: INVESTIGATIONAL ANTI-HYPERTENSIVE DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive hypertension care program; details on dosage and duration not available.
Trial: 8836865
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg alternate day oral aspirin (regular formulation)
Trial: 8836865
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg alternate day oral aspirin (enteric coated formulation)
Trial: 1445490
Drug: Probucol (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (250 mg/day)
Trial: 3918688
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg daily (in smokers)
Trial: 3918688
Drug: Omeprazole 30
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 30 mg daily (in smokers)
Trial: 24548425
Drug: Subcutaneous rFeIFN‐ω
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous rFeIFN‐ω (Virbagen® omega, Virbac, Carros, France) administered via eight injections over four months.
Trial: 24548425
Drug: Oral rFeIFN‐ω
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral rFeIFN‐ω administered daily.
Trial: 24548425
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (subcutaneous rFeIFN‐ω).
Trial: 21436164
Drug: Ibandronate (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibandronate (3 mg intravenous single dose)
Trial: 19473824
Drug: CHO-Meal (control-meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-Meal (control-meal plus 45 g carbohydrates)
Trial: 19473824
Drug: PRO-Meal (control-meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO-Meal (control-meal plus 45 g of casein)
Trial: 19473824
Drug: CHO+PRO-Meal (PRO-meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO+PRO-Meal (PRO-meal plus 45 g carbohydrates)
Trial: 19473824
Drug: CHO-Meal (control-meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO-Meal (control-meal plus 45 g carbohydrates) with casein added
Trial: 19473824
Drug: PRO+CHO-Meal (PRO-meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRO+CHO-Meal (PRO-meal plus 45 g carbohydrates)
Trial: 15572275
Drug: Risperidone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.5 mg)
Trial: 12233993
Drug: Cocaine-dependent outpatients
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine-dependent outpatients (treatment group)
Trial: 29987329
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion
Trial: 1524277
Drug: Terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 120 mg single dose
Trial: 1524277
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg single dose
Trial: 1524277
Drug: Terfenadine 120
RxNorm normalized name: terfenadine 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 120 mg b.i.d. at steady state
Trial: 3932106
Drug: Terfenadine 60
RxNorm normalized name: terfenadine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine 60 mg b.i.d.
Trial: 6350072
Drug: Tioconazole base
RxNorm normalized name: Tioconazole
DrugBank: Tioconazole (DB01007)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tioconazole base 1% cream applied twice daily
Trial: 6350072
Drug: Econazole nitrate
RxNorm normalized name: Econazole Nitrate
DrugBank: Econazole (DB01127)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Econazole nitrate 1% cream applied twice daily
Trial: 24384865
Drug: Rehydration with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehydration with oral rehydration solution (ORS), average consumption of 2040 mL (range; 1800-2500 mL)
Trial: 22375612
Drug: Exenatide twice
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice daily plus sitagliptin and metformin (ADD group)
Trial: 22375612
Drug: Exenatide twice
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide twice daily plus placebo and metformin (SWITCH group)
Trial: 10435066
Drug: Oestradiol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol therapy (2 mg/day)
Trial: 21411832
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg caffeine
Trial: 2182444
Drug: Intermediate-dose i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate-dose i.v. methotrexate (ID-MTX) (4 x 0.5 g/m2)
Trial: 26588236
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg/d
Trial: 31601514
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d, 4 weeks on/2 weeks off
Trial: 31601514
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg/d without AE-related dose reductions
Trial: 31601514
Drug: Pazopanib 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib 800 mg/d with AE-related dose reductions
Trial: 31601514
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d without AE-related dose reductions
Trial: 31601514
Drug: Sunitinib 50
RxNorm normalized name: sunitinib 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib 50 mg/d with AE-related dose reductions
Trial: 28935273
Drug: Etirinotecan pegol
RxNorm normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etirinotecan pegol (EP) administered every 21 days (q21d)
Trial: 19543499
Drug: Rush immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rush immunotherapy (RIT) with Dermatophagoides farinae (Der f) and Dermatophagoides pteronyssinus (Der p)
Trial: 17292595
Drug: TJ‐114 (Saireito)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TJ‐114 (Saireito) at a dose of 9 g/day for 2 days before surgery and for 2 weeks after surgery
Trial: 9742275
Drug: d,l-methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d,l-methadone
Trial: 9742275
Drug: l-methadone
RxNorm normalized name: dl-Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-methadone
Trial: 29944651
Drug: Single-dose oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose oral ciprofloxacin for household contacts within 24 hours of case notification
Trial: 26020438
Drug: Low-radiation-dose CT
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-radiation-dose CT images scored by eight radiologists using morphologic categories proposed by the Fleischner Society guidelines.
Trial: 19170143
Drug: C. colocynthis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C. colocynthis fruit capsules (100 mg, three times a day)
Trial: 11866264
Drug: Anti-H. pylori
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-H. pylori therapy
Trial: 10705200
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade (CAB) with goserelin acetate 3.6 mg and flutamide 250 mg three times daily
Trial: 10705200
Drug: Goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Goserelin acetate 3.6 mg alone
Trial: 3530176
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VCR, NMM, Act.‐D)
Trial: 3530176
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VCR, NMM, Act.‐D, DTIC)
Trial: 3530176
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (VCR, Act.‐D, CCNU, DTIC)
Trial: 3530176
Drug: DTIC-monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC-monotherapy
Trial: 3530176
Drug: Cross over
RxNorm normalized name: Red Cross Canker Sore
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cross over treatment after progression
Trial: 24170750
Drug: Baseline medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline medication adherence
Trial: 20200301
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir twice daily
Trial: 19337555
Drug: CLAs 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLAs 2.5 g (2 g mixture of cis 9‐trans 11 and trans 10‐cis12 CLAs)
Trial: 20374312
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg
Trial: 19337555
Drug: CLAs and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CLAs and vitamin E at above doses
Trial: 12218524
Drug: Clomethiazole edisilate
RxNorm normalized name: Clomethiazole edisilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomethiazole edisilate (0.8%), 225 ml loading dose followed by 100 ml/h maintenance during surgery
Trial: 10334431
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg i.v. verapamil
Trial: 24794816
Drug: Nicotinamide treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotinamide treatment
Trial: 1957127
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b treatment (3 million units thrice weekly)
Trial: 1957127
Drug: Interferon alpha-2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon alpha-2b treatment (6 million units thrice weekly for at least 8 weeks)
Trial: 7011348
Drug: Tiamenidine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiamenidine (3 mg daily)
Trial: 7011348
Drug: Clonidine (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (450 micrograms daily)
Trial: 25414152
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for mild GDM (Control)
Trial: 23661035
Drug: Expectations regarding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectations regarding treatment
Trial: 23661035
Drug: Past experience
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL GEL [Quality Metalcraft Experi-Metal Alcohol Antiseptic 80% Topical Solution Hand Sanitizer Non-sterile Solution]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Past experience with treatment
Trial: 18989348
Drug: Ruboxistaurin 32
RxNorm normalized name: RUBOXISTAURIN
DrugBank: Ruboxistaurin (DB11829)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruboxistaurin 32 mg/day
Trial: 17972425
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (ACE‐I + BB + ARA or ARB)
Trial: 17972425
Drug: Quadruple therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadruple therapy (ACE‐I + BB + ARA + ARB)
Trial: 17972425
Drug: ACE‐I and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE‐I and BB combined with diuretics and often with digoxin
Trial: 12530553
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3.5 g EPA and 2.4 g DHA per day, each as the ethyl ester)
Trial: 12530553
Drug: Evening primrose
RxNorm normalized name: EVENING PRIMROSE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening primrose oil capsules (no detectable EPA or DHA)
Trial: 28684614
Drug: Qred (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qred (200 mg/d)
Trial: 14585635
Drug: Pulsed-dye laser
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed-dye laser (PDL) treatment
Trial: 23137063
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) treatment
Trial: 21523262
Drug: WPC preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPC preparation
Trial: 19257821
Drug: Risedronate (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (15 mg once per week for patients <40 kg; 30 mg once per week for patients >40 kg)
Trial: 17101701
Drug: Removable appliance
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Removable appliance with a palatal crib associated with high-pull chin cup therapy for 12 months
Trial: 7656523
Drug: Glucagon (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (1 mg)
Trial: 11315834
Drug: Epinephrine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (0.3 mg)
Trial: 9223026
Drug: NaHCO3 (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaHCO3 (250 mg (3 mmol).(kg body weight)‐1)
Trial: 8192551
Drug: L-365,260 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 (50 mg)
Trial: 8192551
Drug: L-365,260 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-365,260 (10 mg)
Trial: 3359905
Drug: vodka (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vodka (37.5 ml) in tomato juice
Trial: 28179454
Drug: pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 10 mg/kg i.v. every 2 or 3 weeks until disease progression
Trial: 28179454
Drug: pembrolizumab 2
RxNorm normalized name: pembrolizumab 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pembrolizumab 2 or 10 mg/kg i.v. every 3 weeks
Trial: 28179454
Drug: ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ipilimumab 3 mg/kg every 3 weeks for up to four doses
Trial: 28179454
Drug: investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: investigator's choice of chemotherapy
Trial: 17221013
Drug: Intravenous dipyrone
RxNorm normalized name: dipyrone
DrugBank: Metamizole (DB04817)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dipyrone
Trial: 23494213
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral treatment program
Trial: 18065809
Drug: Atorvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (80 mg single dose)
Trial: 17359691
Drug: Non-reducing group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-reducing group (general pre-operation routine preparation)
Trial: 10971238
Drug: Propofol alone
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol alone (n=120, group A, loading dose 40-60 mg IV, followed by repeated doses of 20 mg)